Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Standard view
Full view
of .
Look up keyword
Like this
0 of .
Results for:
No results containing your search query
P. 1
Vaccines_The Week in Review_12 January 2013.doc

Vaccines_The Week in Review_12 January 2013.doc

Ratings: (0)|Views: 1 |Likes:
Published by davidrcurry

More info:

Published by: davidrcurry on Jan 13, 2013
Copyright:Attribution Non-commercial


Read on Scribd mobile: iPhone, iPad and Android.
download as DOC, PDF, TXT or read online from Scribd
See more
See less





Vaccines: The Week in Review12 January 2013Center for Vaccine Ethics & Policy (CVEP)
This weekly summary targets news, events, announcements, articles and research in the global vaccine ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. Vaccines: The Week in Review is also posted in pdf form and as a set of blog posts at http://centerforvaccineethicsandpolicy.wordpress.com/ . This blog allows full-text searching of over 3,500 entries.Comments and suggestions should be directed to David R. Curry, MS Editor and Executive Director Center for Vaccine Ethics & Policy 
Editor’s Notes:
 - A pdf version of this issue is available on our blog: 
The National Foundation for Infectious Diseases (NFID) announced that it will honorDr. Paul A. Offit with the Maxwell Finland Award for Scientific Achievement
at its Annual Awards Dinner on Tuesday, March 5, 2013. The award will be presented to Dr. Offit “for hisoutstanding work in the pediatric vaccine arena and his ongoing commitment to vaccineadvocacy.” The Award is given to a scientist who has made outstanding contributions to theunderstanding of infectious diseases or public health. The announcement noted that ”Dr. Paul A. Offit is an impassioned advocate for immunization. He has rallied the scientific counterattack against the anti-vaccine movement. Dr. Offit is the co-inventor of the RotaTeg rotavirus vaccinewhich is recommended for universal use in infants in the US and is widely used in othercountries. Dr. Offit is credited with saving countless lives worldwide.” Vijay Samant, president and chief executive officer of Vical, Inc., commented “I believe Dr.Offit is a most appropriate candidate for the Maxwell Finland Awards for his broad influence onthe pediatric vaccine field, from his development of the life-saving rotavirus vaccines, to hisexemplary pediatric practice, to his staunch support of childhood immunization against zealousopponents. His insightful and approachable style of writing has helped bridge the gap betweenmedical research and the general public. His legacy must include both the hundreds of thousands of lives already saved by the rotavirus vaccines, and the million more that will besaved by his advocacy for prudent vaccine policy.” http://www.nfid.org/publications/helix/December-2012.pdf 
Pfizer announced that the European Commission has approved expanding the use ofPrevenar 13
to older children and adolescents aged 6 to 17 years for active immunization forthe prevention of invasive disease, pneumonia and acute otitis media caused by vaccine-typeStreptococcus pneumoniae. Children in this age group who have not previously receivedPrevenar 13 may receive a single dose of the vaccine.http://www.businesswire.com/news/home/20130108005435/en/Pfizer-Receives-European- Approval-Expand-Prevenar-13 
The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc.announced a follow-on collaboration
to advance malaria vaccine development and newvaccination delivery technologies. Researchers “will test whether a novel vaccine approach thatcombines genetically engineered DNA with an innovative vaccine delivery technology calledelectroporation could induce an immune response in humans that protects against malariaparasite infection.” This follow-on agreement for clinical development builds on a 2010 researchand development collaboration between Inovio and MVI. Electroporation “deploys controlledelectrical impulses to create temporary pores in a cell membrane, allowing uptake of thesynthetic DNA. The cell then uses the DNA's instructions to produce proteins that mimic thepresence of the malaria pathogen, with the aim of inducing an immune response that providesprotection against malaria.” Dr. David C. Kaslow , director of MVI, said, "We are excited to bringthis innovative delivery technology into clinical testing to see whether the compelling immuneresponses seen in animal models translate to humans. Determining if and how these potentimmune responses lead to protection against infection with the most deadly form of malaria is ahigh priority in our efforts to develop a next generation malaria vaccine.” http://www.prnewswire.com/news-releases/path-malaria-vaccine-initiative-and-inovio-pharmaceuticals-partner-to-accelerate-development-of-malaria-vaccines-and-innovative-delivery-technologies-185835962.html 
GAVI said it welcomed results from its first ever review by MOPAN (MultilateralOrganisation Performance Assessment Network)
in which it was “…commended for itseffectiveness in increasing access to immunisation and for its focus on results.” GAVI said thereview noted strengths including financial management, accountability checks, countryownership support and relationship management, and that it “was rated adequate, strong orabove for 95% of the key performance indicators as a result of the document review.” Thereview also highlighted areas where performance could be improved, such as iGAVI’s “strategicmanagement, its use of indicators to measure progress towards Paris DeclarationCommitments, the management practices used in its budgeting process and its guidelines onevaluation coverage.” MOPAN is a network of 17 donor countries, representing the majority of worldwide Overseas Development Assistance (ODA), which rates the effectiveness of multilateral organisations. MOPAN members share information, carry out joint assessments anddraw on each other’s expertise in evaluation. This review was led by the governments of France, Spain and Sweden. To serve as a basis for the report, country-level surveys wereundertaken in 15 GAVI-eligible countries, including Bangladesh, Cambodia, the DemocraticRepublic of the Congo, Georgia, Ghana, Honduras, Indonesia, Nicaragua, Niger, Nigeria,
Pakistan, Rwanda, the United Republic of Tanzania, the Republic of Yemen and Zimbabwe.http://www.gavialliance.org/library/news/statements/2013/gavi-recognised-for-effectiveness-and-focus-on-results/ 
IFFIm (International Finance Facility for Immunisation) announced that “threelongtime banking officials with significant international experience joined its board ofdirectors
on 1 January 2013. The 3-year terms were approved by the board in December andinclude:- Cyrus Ardalan, Vice Chairman of Barclays, where he has served in several key roles ingovernment relations, emerging markets and investment banking…- Marcus Fedder, who most recently has focused on microfinance after a long career in banking,during which he held senior positions at Toronto Dominion Bank, CIBC and Deutsche Bank...Christopher Egerton-Warburton, who helped create IFFIm as the lead banker at Goldman Sachsat its creation…The appointments are in conjunction with the expiring term of John Cummins, who rotatedoff the board at year-end 2012, the upcoming expiration of the term of Dayanath Jayasuriya atend-June 2013, and the departure of Arunma Oteh at year-end 2011. “IFFIm is a multilateraldevelopment institution created to accelerate the availability of predictable, long-term funds forhealth and immunisation programmes through the GAVI Alliance in more than 50 of the world’spoorest countries. It has raised more than US$ 3.7 billion in the bond markets, backed by US$6.3 billion in pledges from nine countries.” http://www.iffim.org/library/news/press-releases/2013/iffim-appoints-three-new-members-to-its-board-of-directors/
Update: Polio this week -
As of 09 January 2013
[Editor’s Extract and bolded text] 
- Two years polio-free: January 13 will mark two years since a child was paralyzed by wildpoliovirus in India, a country once considered the most complex challenge to global polioeradication.- Response to Niger outbreak: The first immunization activities start in Niger on 112 January2013, in close coordination with Nigeria. This first outbreak of imported wild poliovirus in 2012is due to virus of Nigerian origin.
- Two new WPV cases were reported in the past week, bringing the total number of WPV casesfor 2012 to 37. Both of the WPV cases occurred in Nangarhar (2 WPV1), a newly infectedprovince, with onset of paralysis on 20 December 2012. Outbreak response immunization in 10districts in Nangarhar will be conducted using bivalent OPV.- No new cases of circulating vaccine-derived poliovirus type (cVDPV) were reported in the pastweek. The total number of cVDPV cases for 2012 remains 4.
- Two new WPV cases were reported in the past week (1 WPV1 from Kano and 1 WPV1 fromKatsina), bringing the total number of WPV cases for 2012 to 121. The most recent case

You're Reading a Free Preview

/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->